The 15-member panel of the Institute for Clinical and Economic Review (ICER) unanimously agreed that Biogen's controversial Alzheimer's disease drug Aduhelm (aducanumab) does not provide more benefit to patients than supportive care, reported Fox Business.
The panel met with Biogen representatives, patients/caregivers and expert neurologists, and voted July 15 on whether Aduhelm provides a net health benefit, if it has other potential benefits and important contextual considerations, and the long-term cost-effectiveness.
"Individuals and families dread Alzheimer's disease, and the first therapy that effectively halts or reverses dementia will warrant a very high price in the US health system," said David Rind, ICER's chief medical officer.
"However, the clinical trial and evidence regarding aducanumab are complex, and we agree with many independent experts that the current evidence is insufficient to know whether or not aducanumab slows the loss of cognition," Rind added.
"After months of delving into the data, and working with patient groups, clinical experts and the manufacturer to gain their perspectives, our judgment remains that the evidence on aducanumab is insufficient to be able to demonstrate that patients get benefits that would outweigh the risks and harms of this treatment," he said.
To read more NewsPoints articles, click here.